February 22, 2021
Aion Therapeutic Announces Closing of Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 6,666,333 units ("Units") at a price of $0.075 per Unit for gross proceeds…
February 22, 2021
Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study
February 22, 2021
Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming…
February 22, 2021
Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process
Toronto, Ontario--(Newsfile Corp. - February 22, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has…
February 22, 2021
Havn Life announces DTC Eligibility of Its Common Shares in the United States
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce today that its common shares are…
February 19, 2021
Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial
London, United Kingdom--(Newsfile Corp. - February 19, 2021) - Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa's Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential…
February 19, 2021
Mindset Pharma Added to North American Psychedelics Index
Toronto, Ontario--(Newsfile Corp. - February 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that…
February 18, 2021
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation
Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing…
February 18, 2021
Pure Extracts and Canada House Wellness Group sign agreement to distribute concentrate products through existing provincial distribution channels
VANCOUVER, British Columbia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) a plant-based extraction company, focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, and Canada…
Track the Horizons Psychedelic Stock Index ETF
February 19, 2021
Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial
London, United Kingdom--(Newsfile Corp. - February 19, 2021) - Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa's Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential…
February 19, 2021
Mindset Pharma Added to North American Psychedelics Index
Toronto, Ontario--(Newsfile Corp. - February 19, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that…
February 18, 2021
Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation
Trial enters pre-implementation stage having met several key milestones towards expanding access to patients with PTSD VANCOUVER, BC, Feb. 18, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing…
February 18, 2021
Pure Extracts and Canada House Wellness Group sign agreement to distribute concentrate products through existing provincial distribution channels
VANCOUVER, British Columbia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) a plant-based extraction company, focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, and Canada…
February 17, 2021
Tryp Therapeutics Completes $2 Million Strategic Financing
La Jolla, California--(Newsfile Corp. - February 17, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce that effective February 16, 2021, it…
February 17, 2021
Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Technology is Expected to Provide Continuous Monitoring
Ehave, Inc. to leverage data and AI to correlate biomarkers for the identification of psychedelic drug administration as a treatment for Chronic pain, Depression (major and persistent), PTSD, Bipolar disorder, General anxiety, ADHD and Schizophrenia MIAMI, Feb. 17, 2021 (GLOBE NEWSWIRE) --…
February 17, 2021
Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technology
DENVER, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the "Company") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital health platform and the world's-first telemedicine application…
February 17, 2021
Psyched Wellness Closes $6,603,000 Bought Deal Private Placement
Toronto, Ontario--(Newsfile Corp. - February 17, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company"), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that further to its…
February 17, 2021
Revive Therapeutics Acquires Unique Psilocybin Assets
TORONTO, Feb. 17, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further to its press release dated…
February 17, 2021
MindMed’s LSD Neutralizer Study Begins
Potential Emergency Off-Switch for Psychedelic Assisted Therapies BASEL, Switzerland, Feb. 17, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced the start of a study for its LSD neutralizer technology intended to shorten…
February 17, 2021
Mindset Pharma Announces U.S. Listing Application for OTCQB Venture Market
Toronto, Ontario--(Newsfile Corp. - February 17, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTC PINK: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to…
February 17, 2021
Havn Life Announces Changes to Board Composition and Departure of Ms. Rasode
Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), announces the departure of Ms. Barinder Rasode as President and as a director of the Company, effective immediately. The Company also announces that its Chief Executive Officer, Mr. Tim…
February 16, 2021
Field Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results
Q3 2021 patient services revenues of $316,329 represent a 235% increase over the previous quarter Field Trip continues to advance development of FT-104, a novel psychedelic molecule with pending patents by accelerating activities in manufacturing and preclinical toxicology to acquire the data…
February 16, 2021
Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr.…
February 16, 2021
Cybin Inc. Releases Financial Highlights and Provides Business Update
Successful bought deal offering brings total capital raised to-date to approximately $90 million Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated tryptamines and phenethylamines Adelia Therapeutics acquisition expands scientific…
February 16, 2021
Pure Extracts Agrees to Licensing deal with Taste-T, LLC the US manufacturer of Fireball Cannabis Gummies
VANCOUVER, British Columbia, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased…
February 16, 2021
Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program
La Jolla, California--(Newsfile Corp. - February 16, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced that Albany Molecular Research ("AMRI")…
February 12, 2021
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
TORONTO, Feb. 12, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously…
February 12, 2021
The Conscious Acquisition Company Announces the First Psychedelic Medicine Focused SPACs
Exchange Listing, LLC and The Conscious Fund announce their partnership and the creation of The Conscious Acquisition Company. The new venture is a range of Special Purpose Acquisition Company (SPACs) aimed to create long-term value in psychedelic medicine. The pioneering SPACs will take a thematic…
February 11, 2021
Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program
TORONTO, Feb. 11, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its cannabinoid…
February 11, 2021
MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
ZUG, Switzerland, Feb. 11, 2021 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic…
February 11, 2021
Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor
La Jolla, California--(Newsfile Corp. - February 11, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp" or the "Company") a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory…
February 10, 2021
Field Trip Health Ltd. Schedules Third Fiscal Quarter 2021 Financial Results Conference Call for Wednesday, February 17, 2021 at 8:00 am ET
TORONTO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP, FTRP.WT, OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its third fiscal quarter ended December…
February 10, 2021
Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates
Toronto, Ontario--(Newsfile Corp. - February 10, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that…
February 10, 2021
NeonMind Submits Applications to Health Canada for Product Formulas to Support Cognitive and Immune Function and to Fight Stress
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), announces that through its consumer products division, it submitted on February 2, 2021 four applications to Health Canada's Natural and Non-prescription Health…
February 10, 2021
Pure Extracts Announces Its First Commercial Sale of CBD Oil on the Wholesale Market
VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic…
February 9, 2021
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering
TORONTO, Feb. 09, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further to its press releases dated…
February 9, 2021
Field Trip Health Ltd. Announces Official Opening of Psychedelic Research and Cultivation Facility in Jamaica
TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce the official opening of the Field Trip Natural Products Limited Research and Development…
February 8, 2021
Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller
La Jolla, California--(Newsfile Corp. - February 8, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with Dr.…
February 8, 2021
Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing
Acquisition expands Numinus' presence while improving psychedelic-assisted therapy landscape in Canada VANCOUVER, BC, Feb. 8, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting…
February 5, 2021
Numinus Engages Native Ads Inc. for Digital Media Services
VANCOUVER, BC, Feb. 5, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, is pleased to announce…
February 5, 2021
Mindset Files Multiple Final Patent Applications on Its Novel Psilocybin-Inspired Compounds
Toronto, Ontario--(Newsfile Corp. - February 5, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a leading drug discovery and development company focused on the development novel next generation psilocybin-inspired medicines and related technologies, is pleased to…
February 5, 2021
Tryp Therapeutics Announces Strategic Investment of $2,000,000
La Jolla, California--(Newsfile Corp. - February 5, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp") is pleased to announce a non-brokered private placement (the "Placement") of 3,333,333 million units (the "Units") at a price of $0.60 per Unit, to raise gross proceeds of approximately $2.0…
February 4, 2021
Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development
Vancouver, British Columbia--(Newsfile Corp. - February 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Jonna…
February 4, 2021
Cybin Announces Closing of Upsized Bought Deal Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO–(Official Release)–Cybin Inc. (NEO: CYBN) (“Cybin” or the “Company”), (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, is…
February 4, 2021
Psyched Wellness Provides Update on Antioxidant and Anti-Inflammatory Study of Muscimol
Toronto, Ontario--(Newsfile Corp. - February 4, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share an update on the…
February 3, 2021
Aion Therapeutic Grants Stock Options; Announces Management Change
Toronto, Ontario--(Newsfile Corp. - February 3, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has granted and issued options for the purchase of up to 4,000,000 common shares of the Company to a number of the Company's officers, directors…
February 3, 2021
Mydecine Innovations Group Appoints Josephine Wu to Board of Directors
DENVER, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream…
February 3, 2021
Pure Extracts Announces Submission for Class 1 Natural Product Number (NPN)
VANCOUVER, British Columbia, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic…
February 3, 2021
Tryp Therapeutics Announces Appointment of Greg McKee as Executive Chairman
La Jolla, California--(Newsfile Corp. - February 3, 2021) - Tryp Therapeutics (CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, needs is pleased to announce the appointment of Greg McKee…
February 2, 2021
Psyched Wellness to Participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference
Toronto, Ontario--(Newsfile Corp. - February 2, 2021) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched") a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushroom derived products, is pleased to…
February 2, 2021
Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on license…
February 2, 2021
Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board
La Jolla, California--(Newsfile Corp. - February 2, 2021) - Tryp Therapeutics, a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical needs, is pleased to announce that it has added world renowned psychedelic scientist, Dr. Robin Carhart Harris to…
February 2, 2021
Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.
Havn Life to supply psychedelic compounds for clinical trials launched by neuroscience and technology leader HealthTech Connex Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of…
February 1, 2021
Mindset Pharma Retains Corporate Development Advisors
Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has…
February 1, 2021
Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression
MIAMI, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, is announcing plans to roll out its ketamine home delivery platform known as KetaDASH. The backbone for KetaDASH will be…
February 1, 2021
Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
DENVER, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream…
February 1, 2021
Mindset Selects Compounds from Its Third Psilocybin-Inspired Drug Family to Move into in vivo PoC Studies
Toronto, Ontario--(Newsfile Corp. - February 1, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has…
January 29, 2021
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts
Key milestones met in ongoing trials, expanding national footprint, and enhanced research capabilities ensure Numinus' continued growth VANCOUVER, BC, Jan. 29, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a health care and research company developing and…
January 28, 2021
Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland
DENVER, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine…
January 28, 2021
Field Trip Health Ltd. Common Shares to Trade on the OTCQX Best Market
TORONTO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, is pleased to announce its common shares have been approved for trading on the OTCQX® Best Market (“OTCQX”)…
January 27, 2021
Pure Extracts Announces DTC Eligibility of Its Common Shares in the United States
VANCOUVER, British Columbia, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, focused on cannabis, hemp, functional mushrooms, and the rapidly emerging psychedelic…
January 27, 2021
Ehave Looks to Expand KetaDASH to Palliative Care
MIAMI, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it is exploring how palliative patients could benefit from its Ketamine home delivery platform, KetaDASH.…
January 27, 2021
Cybin Included in First Psychedelic Exchange Traded Fund
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, – Cybin Inc. (NEO: CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it is among the select…
January 27, 2021
Mindset Pharma Announces Listing on the Frankfurt Stock Exchange
Toronto, Ontario--(Newsfile Corp. - January 27, 2021) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) ("Mindset" or the "Company"), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that its…
Get Bi-Weekly Updates
Subscribe to the Market Insights Report
Each Wednesday and Saturday, we will send you a review of the latest price movements, financial analysis, and original insights on the emerging financial landscape of the psychedelic industry.
Get Bi-Weekly Updates
Subscribe to the Market Insights Report
Each Wednesday and Saturday, we will send you a review of the latest price movements, financial analysis, and original insights on the emerging financial landscape of the psychedelic industry.